Literature DB >> 1337037

Splenic embolization prior to myelosuppressive treatment in hepatocarcinoma and active chronic hepatitis.

J I Bilbao1, B Sangro, J M Longo, J M Zozaya, A Fernández-Virgós, J D Aquerreta, O Beloqui, J Prieto.   

Abstract

In the treatment of active chronic hepatitis and hepatocellular carcinoma some effective drugs can produce myelosuppression. Hypersplenism may considerably limit the dosage of such drugs. Splenectomy is an effective treatment for hypersplenism, although it is not without complications. Partial splenic embolization is a good and safe procedure; 15 patients were treated in order to achieve higher platelet and leukocyte counts. Embolization has been performed with gelfoam with local and systemic antibiotics (Spigos' protocol) and 50-75% of the splenic parenchyma was infarcted. All patients could be treated for the underlying hepatopathy with adequate dosages of interferon or chemotherapeutic drugs.

Entities:  

Mesh:

Year:  1992        PMID: 1337037     DOI: 10.1016/0720-048x(92)90109-m

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  3 in total

1.  Partial splenic embolization in a child with hereditary spherocytosis.

Authors:  M Jiménez; C Azcona; L Castro; J I Bilbao; P León; L Sierrasesúmaga
Journal:  Eur J Pediatr       Date:  1995-06       Impact factor: 3.183

2.  Partial splenic embolisation and improvement of hypersplenism before liver transplantation.

Authors:  C Villaizán Pérez; J Román Pérez; J I Bilbao Jaureguízar; L Sierrasesúmaga Ariznavarreta; I Villa-Elízaga
Journal:  Arch Dis Child       Date:  1995-03       Impact factor: 3.791

3.  Guidelines on the use of gelatin sponge particles in embolotherapy.

Authors:  Shiro Miyayama; Koichiro Yamakado; Hiroshi Anai; Daisuke Abo; Tetsuya Minami; Haruyuki Takaki; Taishi Kodama; Takashi Yamanaka; Hideyuki Nishiofuku; Kengo Morimoto; Takeshi Soyama; Yu Hasegawa; Koichi Nakamura; Tomoaki Yamanishi; Morio Sato; Yasuo Nakajima
Journal:  Jpn J Radiol       Date:  2014-02-08       Impact factor: 2.374

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.